Journal article
Docetaxel effectively mobilizes peripheral blood CD34 cells
HM Prince, GC Toner, JF Seymour, D Blakey, P Gates, S Eerhard, P Chapple, D Wall, M Quinn, S Juneja, M Wolf, EH Januszewicz, G Richardson, J Scarlett, P Briggs, M Brettell, D Rischin
Bone Marrow Transplantation | NATURE PUBLISHING GROUP | Published : 2000
Abstract
We prospectively evaluated docetaxel (100 mg/m2) with G-CSF (10 μg/kg S.C., daily) for mobilization efficiency in 26 patients with breast cancer. The minimum target yield was >4.5 x 106 CD34+ cells/kg (optimum = 9 x 106/kg), sufficient to support the subsequent three cycles of high-dose therapy (HDT). The peak days for peripheral blood (PB) CD34+ cells were day 8 and day 9. Seven collections began on day 7, 16 on day 8 and three on day 9. The median peripheral blood progenitor cell (PBPC) CD34+ cell content ranged from 1.2 to 5.9 x 106/kg per day during days 7 to 11 with a median CD34+ content of the total 72 PBPC collections of 3.4 x 106/kg (0.07-15.6). Fifteen patients obtained a PBPC coll..
View full abstract